Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870261 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4MCHR1NPY1RNPY2R | |
| SCHEMBL1870265 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4MCHR1NPY1RNPY2R | |
| SCHEMBL1869027 | 0.81 | NPY1R (0.51) | CHRNB2CHRNA4MCHR1NPY1RNPY2R | |
| SCHEMBL1869029 | 0.81 | NPY1R (0.51) | CHRNB2CHRNA4MCHR1NPY1RNPY2R | |
| SCHEMBL1869032 | 0.81 | NPY1R (0.51) | CHRNB2CHRNA4MCHR1NPY1RNPY2R | |
| SCHEMBL1881579 | 0.78 | NPY1R (0.39) | NPY1RNPY2RNPY4RNPY5RKDM4E | |
| SCHEMBL2656329 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4ABL1 | |
| SCHEMBL20255573 | 0.78 | PIM1 (0.32) | ABL1CHRNA7 | |
| SCHEMBL18291202 | 0.78 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL16691251 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2017-08-31 | — | — | US | disclosed |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2445883-B1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.